331 related articles for article (PubMed ID: 33994437)
1. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.
Nishimiya N; Tajima K; Imajo K; Kameda A; Yoshida E; Togashi Y; Aoki K; Inoue T; Nakajima A; Utsunomiya D; Terauchi Y
Intern Med; 2021 Nov; 60(21):3391-3399. PubMed ID: 33994437
[TBL] [Abstract][Full Text] [Related]
2. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.
Inoue M; Hayashi A; Taguchi T; Arai R; Sasaki S; Takano K; Inoue Y; Shichiri M
J Diabetes Investig; 2019 Jul; 10(4):1004-1011. PubMed ID: 30461221
[TBL] [Abstract][Full Text] [Related]
3. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
5. Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by
Hu L; Shao X; Qiu C; Shao X; Wang X; Niu R; Wang Y
BMC Endocr Disord; 2020 May; 20(1):75. PubMed ID: 32460891
[TBL] [Abstract][Full Text] [Related]
6. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Cusi K; Bril F; Barb D; Polidori D; Sha S; Ghosh A; Farrell K; Sunny NE; Kalavalapalli S; Pettus J; Ciaraldi TP; Mudaliar S; Henry RR
Diabetes Obes Metab; 2019 Apr; 21(4):812-821. PubMed ID: 30447037
[TBL] [Abstract][Full Text] [Related]
7. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
[TBL] [Abstract][Full Text] [Related]
8. Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes.
Hao Z; Sun Y; Li G; Shen Y; Wen Y; Liu Y
BMC Endocr Disord; 2022 Feb; 22(1):37. PubMed ID: 35144596
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
[TBL] [Abstract][Full Text] [Related]
11. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
[TBL] [Abstract][Full Text] [Related]
12. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study.
Hiruma S; Shigiyama F; Kumashiro N
Diabetes Obes Metab; 2023 Jun; 25(6):1576-1588. PubMed ID: 36749298
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study.
Eroğlu İ; Iremli BG; Erkoc A; Idilman IS; Yuce D; Kutukcu EC; Akata D; Erbas T
J Clin Densitom; 2024; 27(2):101479. PubMed ID: 38447349
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.
Kabil SL; Mahmoud NM
Eur J Pharmacol; 2018 Jun; 828():135-145. PubMed ID: 29608898
[TBL] [Abstract][Full Text] [Related]
18. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly.
Eroğlu İ; Iremli BG; Idilman IS; Yuce D; Lay I; Akata D; Erbas T
J Clin Endocrinol Metab; 2023 Dec; 109(1):e119-e129. PubMed ID: 37590020
[TBL] [Abstract][Full Text] [Related]
20. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice.
Tanaka K; Takahashi H; Katagiri S; Sasaki K; Ohsugi Y; Watanabe K; Rasadul IMD; Mine K; Nagafuchi S; Iwata T; Eguchi Y; Anzai K
Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E492-E503. PubMed ID: 32017594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
